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Summary: 
Prevalence and characteristics of DM in TB patients vary considerably between countries, 
underlining the need for country and setting specific information. However, in all four countries, 
the majority of DM among TB patients was previously diagnosed but poorly controlled. Amongst 
individuals with TB-DM DM complications were highly prevalent as were comorbidities and 
CVD risk was raised. 
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Abstract: 
Background. Diabetes mellitus (DM) increases the risk of active tuberculosis (TB) and 
worsens TB outcomes, putting TB control in jeopardy especially in TB endemic countries 
with rising DM prevalence rates. We assessed DM status and clinical correlates in TB 
patients across settings in Indonesia, Peru, Romania and South Africa. 
Methods. Age-adjusted DM prevalence was estimated using laboratory glycated 
haemoglobin (HbA1c) or fasting plasma glucose (FPG) in TB patients. Detailed and 
standardized socio-demographic, anthropometric and clinical measurements were made. 
Characteristics of TB patients with or without DM were compared using multi-level 
mixed effect regression models with robust standard errors.  
Results. Of 2185 TB patients (median 36.6 years, 61.2% male, 3.8% HIV-infected), 
12.5% (267/2128) had DM, 1/3 of whom were newly diagnosed. Age-standardized DM 
prevalence ranged from 10.9% (South Africa) to 19.7% (Indonesia). Median HbA1c in 
TB-DM patients ranged from 7.4% (Romania) to 11.3% (Indonesia). Compared to those 
without DM, TB-DM patients were older with higher Body Mass Index (BMI) (p-
value<0.05). Compared to those with newly diagnosed DM, TB patients previously 
known to have DM had higher BMI and HbA1c, less severe TB, and more frequent 
comorbidities, DM complications and hypertension (p-value<0.05). 
Conclusions: We show that DM prevalence and clinical characteristics of TB-DM vary 
considerably between countries. Diabetes is mostly known but untreated, hyperglycemia 
is often severe, and many patients with combined TB and DM have significant 
cardiovascular disease risk and severe TB, underlining the need to improve strategies for 
better clinical management of combined TB and DM.  
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Introduction 
Prevalence of type 2 Diabetes Mellitus (DM) has been increasing in low and middle-
income countries (LMICs), in areas that also have high TB incidence [1, 2]. DM 
increases the risk of active TB 3-fold and worsens disease outcomes[3]. There were about 
10 million cases of TB and 1.3 million deaths due to TB globally in 2017 [4]. Global TB 
incidence rates are currently modestly declining, and rising DM prevalence threatens 
global TB control [4].Despite expanding evidence on the effect of DM on TB risk and 
outcome, and increasing insights upon mechanisms underlying these effects[5], there are 
limited global data on those with combined TB and DM. Neither the Global Tuberculosis 
Report (2018) [4] or related World Health Organization (WHO) documents report TB-
DM numbers worldwide (in contrast to the national level data on TB-HIV), which makes 
assessment of the burden of this co-morbidity challenging. Much of the available TB-DM 
data is based on retrospective studies, which could underestimate the scale of TB-DM 
comorbidity, particularly as a high proportion of DM is believed to be undiagnosed in 
LMICs[6]. Furthermore, most studies have been conducted on cohorts of TB patients 
using routine or administrative data (e.g. TB program registries) in which key risk factor 
and clinical data associated with DM (such as hypertension, anthropometric measures, 
cardiovascular health, DM duration, medication or control) are not routinely recorded. 
This data gap constrains capacity to provide a complete characterization of patients with 
TB-DM and hinders the ability to design appropriate TB-DM screening and management 
strategies. 
As part of an EU-funded consortium[7], TB patients from four epidemiologically distinct 
settings (Indonesia, Peru, Romania and South Africa) were investigated for co-morbid 
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DM, facilitating standardized, prospective comparison of populations with differences in 
DM and TB prevalence, ethnicity and health systems. We report the country specific, 
age-adjusted prevalence and clinical characteristics of TB patients presenting with 
previously diagnosed DM, newly diagnosed DM, and intermediate hyperglycaemia, 
along with an evaluation of possible risk factors, amongst newly diagnosed TB patients in 
each setting. 
Material and methods 
Study design and study population 
This study was part of TANDEM[7], a consortium exploring the interaction between TB 
and DM. Details of the sites and definitions were described elsewhere[8].  
Study measurements and definitions 
We defined individuals with pulmonary TB if they initiated treatment at a local TB 
program, based on bacteriological (sputum smear, sputum culture or Xpert test), 
radiological and/or clinical evidence. Further details are published elsewhere[9, 10] and 
are freely available in online appendices[8]. 
All participants underwent laboratory HbA1c testing (using the High Performance Liquid 
Chromatography method), as recommended by WHO for DM screening,[11] regardless 
of their previous DM status. Random plasma glucose (RPG) was measured and if >110 
mg/dL but <200 mg/dL (the recognised cut point for diagnosing DM if symptomatic) this 
was also followed with a fasting blood glucose (FPG) test. Patients were deemed to have 
DM if they had repeated tests (HbA1c, RPG or FPG) above the diagnostic threshold, see 
Appendix 1.  
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‘Previously diagnosed DM’ was defined as any patient who self-reported a doctor 
diagnosis of DM and was either taking standard anti-DM drugs at the time of recruitment 
or had a subsequent study HbA1c of ≥6.5%. ‘Newly diagnosed DM’ was defined 
principally based on repeated laboratory testing (see Appendix 1), mostly HbA1c. 
Intermediate hyperglycaemia (or ‘pre-diabetes’; raised blood glucose or HbA1c above 
normal, but below the threshold for identifying DM) was defined as patients with a single 
measurement of either FBG in the pre-DM range (6.1–7.0 mmol/l) or HbA1c in the 
intermediate range (6.0-6.4%) [12](See Appendix 1). Evaluation of the performance of 
these laboratory tests for diagnosis of DM in TB patients in a TANDEM cohort has 
recently been published[9]. 
Underweight was defined as BMI <18 kg/m
2
; normal weight BMI of 18 kg/m
2
 – 24.9 
kg/m
2
; overweight BMI  25kg/m
2
-29.9kg/m
2
; and obesity ≥30 kg/m2. In Indonesia 
accepted BMI categories for South Asian populations were used; overweight was defined 
as BMI 23kg/m
2
-27.49 kg/m
2 
and obesity as ≥ 27.5 kg/m2 [13]. Kidney disease was 
defined according to the National Kidney Foundation guidelines [14]. Principal 
Component Analysis was performed to build a socio-economic status index classifying 
study populations from each country in to quintiles based on asset ownership by patients 
that included non-sellable (possession of a bank account, type of sanitation facility, 
household water source) and sellable assets (e.g. stove, refrigerator, washing machine, 
television). [15].   
Family history of DM was defined by self-report of having either a parent, sibling or 
child with DM. Smoking status was recorded from self-report of currently smoking 
(including those who had quit for less than 6 months), past smokers or having never 
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smoked. Hypertension was categorised as follows; pre-hypertension systolic or diastolic 
120/80-129/80 mmHg, Stage I systolic or diastolic 130/80-139/89 mmHg, Stage II 
systolic or diastolic over 140/90 mmHg[16]. Ten year risk of a fatal or major 
cardiovascular event (myocardial infarction or stroke, using 
WHO/ISH Cardiovascular Risk Prediction Charts)[17] and the Charlson comorbidity 
index was calculated[18].  To assess TB severity, we used TB score, which is a simple 
clinical score used for clinical monitoring of TB, and haemoptysis[19]. 
Data analysis 
We used REDCap 6.9.1 [20] for data collection and management and STATA 15.0 
(StataCorp, Texas, USA) for statistical analysis. Categorical variables were presented 
with their frequencies and continuous variables summarized using mean and standard 
deviation (SD) or where appropriate median and interquartile ranges (IQR). Between 
country comparisons were done using the non-parametric Kruskal-Wallis and Chi-square 
tests were performed for categorical variables and for continuous variables, t-test or 
ANOVA. The crude prevalence of DM was calculated for each country overall and 
stratified by age group. A directly standardised prevalence rate was also calculated using 
the World Standard Population as a reference [21]. Factors potentially associated with 
prevalent DM were assessed by calculating crude odds ratios. All factors significant at 
P<0.15 in this univariate analysis were then included in a multivariate model. A multi-
level mixed effect regression model was used, with country entered as a random error 
term (representing a random intercept) and robust standard errors calculated using 
“country” as a cluster variable to account for the clustering of TB-DM patients within 
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countries. In sensitivity analyses, alternative models were explored where country was 
entered as a fixed effect and interaction terms included between age groups and country. 
Ethics 
This study was approved by the Institutional Review Board (IRB) at the London School 
of Hygiene and Tropical Medicine as the TANDEM Coordinating Centre (Ethics 
Reference Number 6449), and approved by the local IRB at each site. All participants 
were provided with an information sheet explaining the study and provided written 
informed consent. 
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Results 
A total of 2185 pulmonary TB patients were enrolled (Indonesia n=748; Peru n=600; 
Romania n=506 and South Africa n=331). Most patients were male (61.2%), the median 
age was 36.6 years (IQR: 26.0-49.1) and 82 patients (3.8%) were HIV positive, the 
highest proportion from South Africa (9.7%) (Table 1). Of the TB patients recruited, 
78.8% had bacteriologically confirmed disease, either positive on culture (78.8%), or 
sputum smear (72.5%). One quarter of patients (24.6%) reported a previous TB episode. 
More than half reported having ever smoked, with the highest frequencies in South Africa 
(86.1%) and Indonesia (62.0%). The overall median BMI was 19.6 kg/m
2
 in males and 
20.6 kg/m
2
 in females with 2.2% of patients obese, highest in Peru at 3.7% (Table 1).  
Of the 2185 patients, 57 were missing data on DM diagnostic tests. A total of 267 TB 
patients had confirmed DM after repeated testing; a crude prevalence of 12.5% (95% CI 
11.1% to 14.0%). Age standardised DM prevalence was highest in Indonesia at 19.7% 
(95% CI:16.8%-22.5%), similar in Peru (12.3%; 95%CI:9.2%-15.3%) and Romania 
(12.3%; 95% CI: 9.7%-15.0%), and lowest in South Africa at 10.9% (95%CI: 7.0%-
14.9%). More than two-thirds of diabetes detected in this study had already been 
previously diagnosed; 12.8% of TB patients in Indonesia, 5.8% in Peru, 6.9% in Romania 
and 5.1% in South Africa. There were substantial between-country differences in HbA1c 
values among TB-DM patients with a median HbA1c of 11.3% among TB-DM patients 
in Indonesia, 10.6% in Peru, 7.4% in Romania and 10.1% in South Africa.  
Compared to TB patients without DM, TB-DM patients were more frequently smear 
(72.7% vs 80.2%, p=0.009) and culture positive (81.4% vs 91.5%, p<0.001, table 3). 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz284/5431210 by London School of H
ygiene & Tropical M
edicine user on 16 April 2019
  12 
TB patients with DM were older (median age 51.0 vs. 33.0 years, p<0.001), had higher 
BMI (21.9 vs 19.6 kg/m2, p<0.001) and lower waist-hip ratios (Male 0.86 vs 0.89, 
p<0.001; Female 0.83 vs 0.87 <0.001), lower socioeconomic status (wald test p<0.001), 
were more likely to have a family history of DM (aOR 3.7 (1.8 - 7.3), p<0.001) and less 
likely to have been previously treated for TB (16.9% vs 25.7%, p=0.02 ) when compared 
to those without DM (tables 2 and 3). Haemoptysis was slightly more common in TB-
DM patients (30.0% vs 26.6%, p =0.1), and TB Score was higher among TB-DM patients 
in Indonesia.  Individuals with TB-DM were also more likely to have more than 10% risk 
of a major CVD event occurring within 10 years compared to those with TB (24.5% vs 
5.5%, table 3). In female patients, anaemia was consistently less frequent among those 
with DM (42.1% vs 52.1% overall, p=0.001), but there was little difference in anaemia 
prevalence amongst men except in Indonesia (56.1% TB only vs 29.5% TB-DM, 
p<0.001).  
TB patients with newly and previously diagnosed DM were of similar age (52.1 vs 51.0; 
Table 4). However, compared to TB patients with previously known DM, those with a 
new DM diagnosis had a worse TB score on diagnosis (77.4% had a score of 3 or above, 
compared with 65.6% of known DM patients, p=<0.001) suggesting greater TB disease 
severity, lower BMI (20.0 vs 22.5, p=0.02) and lower HbA1c (8.0% vs 10.9%, p=0.05). 
They were also less likely to have a family history of DM (19.1% vs 43.2%, p<0.001), 
had lower Charlson co-morbidity index (CMI) scores (2.4% vs 47.0% had a score ≥2, 
p<0.001) and fewer DM complications including hypertension and macro or 
microvascular disease (2.4% vs 43.2%, p<0.001) (Table 4).   
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Despite the poor DM control evidenced by high HbA1c results, a significant proportion 
of those with a previous DM diagnosis reported taking insulin (20.2%) or metformin 
(61.2%). The overall poor health of this group of patients was clear from the high 
proportion (20.0%) reporting at least one DM-attributable hospital admission in the 
preceding 5 years.  
TB patients with intermediate hyperglycaemia (or “pre-diabetes”) were slightly older 
compared to those with TB only (median age of 39 vs 32), but otherwise appeared to be 
more like TB-only patients than TB-DM patients in terms of BMI and disease 
characteristics (Supplementary Table 1). 
Discussion 
In this multi-country cohort patients with newly diagnosed TB had a high prevalence of 
both newly diagnosed (3.8%) and previously known (8.4%) DM. Diabetes prevalence 
amongst TB patients varied between countries, as did the proportion of known versus 
newly diagnosed DM. DM was very uncommon in younger patients, with the risk of 
having DM increasing substantially for those 35 years and over, and between 20-35% of 
TB patients aged over 50 years old having new or previously diagnosed DM. Most 
patients had been diagnosed with DM relatively recently, many within the past year. 
Amongst these individuals TB may have been their first complication of DM, and 
amongst those newly diagnosed with DM their incident TB disease revealed their 
underlying DM.  
TB patients with known DM were characterised by poor glycaemic control despite their 
knowledge of their DM status (median HbA1c 10.9% with outlying values as high as 
17%). Better glycaemic control is known to reduce future risk of macro- and 
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microvascular disease and would likely reduce the risk of many infections among DM 
patients[22]. Though direct evidence that enhanced glycaemic control reduces TB risk is 
lacking, the increased risk of TB amongst individuals with DM [6] and the association 
with poorer TB treatment outcomes[3], suggest that improved glycaemic control should 
be amongst the suite of interventions to prevent TB especially in areas with high TB 
prevalence. Cases of TB in poorly controlled DM may be viewed as missed opportunities 
for TB prevention; conversely, incident TB, when adequately treated, provides a “second 
chance” to re-engage previously neglected patients back into DM care. Incident TB also 
offers an opportunity for new diagnosis and management of previously unrecognised 
DM, potentially reducing downstream DM-related morbidity. 
Our findings are consistent with earlier studies that show age is an important risk factor 
for DM among TB patients [23-25]. Obesity was also strongly associated with diabetes 
[26], in line with some [27-29] but not all studies [30]. Whilst obesity is well known to be 
a strong risk factor for diabetes in the general population, it has not always been 
identified as a risk factor among TB patients, likely due to the weight loss that often 
accompanies TB disease. Besides obesity and increasing age, family history of DM was 
also strongly associated with having DM in this population. 
At 21%, the prevalence of intermediate hyperglycaemia (“pre-diabetes”) identified in TB 
patients was higher than expected, although a rising prevalence of intermediate 
hyperglycaemia has been reported in LMICs [31]. This figure would have even been 
higher based on point-of-care HbA1c results[10], or use of the lower American Diabetes 
Association cut-point. Caution is advised in interpreting the significance of intermediate 
hyperglycemia as transient hyperglycaemia may occur in hypermetabolic inflammatory 
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conditions and infections, including TB[32] (see Supplementary Figure 1)[9]. The 
definition of intermediate hyperglycaemia itself is under scrutiny as DM only develops 
within 10 years in <50% of those identified with pre-DM based on a single FBG or 
HbA1c test [33], and uncertainty about the cut-point when using HbA1c. Our data 
suggest that TB patients with intermediate hyperglycaemia were clinically more like 
those without diabetes than people with diabetes. Over- diagnosis and over-treatment of 
intermediate hyperglycaemia [34] may increase potentially unnecessary risks (stress, drug 
adverse events) in vulnerable populations such as those with TB, and does not appear 
warranted on the basis of our data. 
Patients with previously diagnosed DM often had serious comorbidities and DM 
complications such as chronic kidney disease which itself is an independent risk factor 
for TB [35], and microvascular and/or macrovascular complications. Patients with newly 
diagnosed DM had fewer DM complications, but more severe TB, despite better 
glycaemic control, suggesting that some of those newly diagnosed were experiencing 
“transient hyperglycaemia” due to severe TB. In general, TB patients with diabetes 
appeared to have somewhat worse TB disease compared to those without DM.  
For patients with TB-DM an important consideration in the aftermath of successful TB 
treatment is glycemic control and management of cardiovascular risk associated with 
DM. Despite poor glycemic control, only 20% of TB patients with previously known DM 
used insulin, and only 61% used metformin. Also, hypertension was common but often 
untreated. These figures are in line with significant gaps in management of DM in general 
that we found in these same settings[36]. 
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The between-country heterogeneity for certain parameters (HbA1c and BMI 
distributions) highlights the inherent variability across different populations and 
epidemiological settings. Though this observation is a finding that stresses the importance 
of understanding the local in-country epidemiology, it adds complexity to analyses which 
pool data from such diverse sites. We used robust standard errors to adjust for clustering 
within sites, and included country as a random effect in our regression modelling.  
A potential limitation of this study is that laboratory tests were taken at the time of 
diagnosis and confirmatory tests up to 2 weeks later. Elevated measurements may 
therefore reflect stress hyperglycaemia, overestimating DM prevalence [37] although 
available repeated HbA1c or FBG tests at the end of TB treatment remained abnormal in 
the large majority (not shown).  
This study has many strengths: all patients were screened for DM with HbA1c, a 
standardized and validated measure in accredited laboratories, and the recruitment 
processes were standardized (using case record forms, standard operating procedures, and 
standardized definitions of all major variables), which enhances the cross-site 
comparability. In contrast to many studies of DM prevalence among TB patients, a 
repeated laboratory based measure was used for screening. Many earlier studies have 
been limited to a single test, often using point of care methods, not universally considered 
appropriate for DM diagnosis [11]. The case-definition used here is thus likely to be more 
robust. Recruitment criteria were specific, but sufficiently flexible to ensure the 
representativeness of participants within sites, and included microbiological assessment 
of TB status.  
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Our data enforce recently updated recommendations regarding DM screening and 
management among TB patients published by the UNION (International Union Against 
Tuberculosis and Lung Diseases) and World Diabetes Foundation[38]. These aimed to 
help front-line health workers at TB and DM clinics and highlight some of the challenges 
in management of comorbid disease[22]. However, stronger evidence (particularly in 
implementation of comorbidity care & treatment) are urgently needed. Further 
longitudinal studies exploring the role and importance of transient hyperglycaemia in TB 
patients and its association with future DM are also essential, as are studies examining the 
longer-term effects of DM screening and management on both TB and DM outcomes. 
Future studies should explore improved models of care, such as training of health care 
professionals to deliver integrated management of TB-DM in primary care in LMIC. 
Such integrated management could increase uptake of appropriate secondary preventive 
therapies for patients with TB-DM at high risk of cardiovascular disease, and may also 
improve TB treatment outcomes[39], given the high prevalence of uncontrolled DM at 
baseline in our cohort. Attention should also be paid to health systems interventions to 
enhance and promote referral to local DM services after the end of TB treatment. Despite 
this evident need, there are no published randomized controlled trials that have explored 
integrated management options, and a paucity of on-going studies addressing these key 
clinical issues[39, 40].  
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Table 1. Baseline characteristics 
Characteristics  
Total 
(N=2185) 
Indonesia 
(N=748) 
Peru 
(N=600) 
Romania 
(N=506) 
South Africa 
(N=331) 
Median Age (IQR)  36.6 (25.5-49.1) 37.0 (27.0-49.0) 30.0 (22.0 - 43.0) 43.0 (30.0 – 54.0) 35.0 (28.0 - 48.0) 
≥35 years old (%)  1171 (53.6%) 416 (55.6%) 246 (41.0%) 341 (67.4%) 168 (50.8%) 
Gender (%) Male 1337 (61.2%) 426 (57.0%) 348 (58. 0%) 358 (70.8%) 205 (61.9%) 
Median BMI kg/m2 
(IQR) 
 
All 
Male 
Female 
19.9 (17.7-22.5) 
19.6 (17.5-21.9) 
20.6 (18.0-23.4) 
18.2 (16.3-20.6) 
17.8 (16.1-19.7) 
19.2 (16.7-22.1) 
22.1 (20.0-24.4) 
21.7 (19.9-23.8) 
22.7 (20.0-25.3) 
20.3 (18.7-22.2) 
20.3 (18.8-22.0) 
20.3 (18.3-22.6) 
18.5 (17.0-20.8) 
18.2 (16.6-20.0) 
19.5 (17.7-22.6) 
Obesity (BMI≥30) 1  49 (2.2%) 14 (1.9%) 22 (3.7%) 4 (0.8%) 9 (2.7%) 
HIV status2 (%) Positive 82 (3.8%) 26 (3.5%) 23 (3.8%) 1 (0.2%)   32 (9.7%) 
Sputum smear 
result  
Positive 1583 (72.5%) 629 (84.1%) 387 (64.5%) 345 (68.2%) 222 (67.1%) 
(%) Missing 34 (1.6%) 1 (0.1%) 2 (0.3%) 13 (2.6%) 18 (5.4%) 
Sputum culture 
result  
Positive 1721 (78.8%) 610 (81.6%) 491 (81.8%) 390 (77.1%) 230 (69.5%) 
(%) Missing 113 (5.2%) 25 (3.3%) 2 (0.3%) 25 (4.9%) 11(30.1%) 
Previous TB (%) Yes 538 (24.6%) 185 (24.7%) 123 (20.5%) 97 (19.2%) 133 (40.2%) 
Fever, ≥38℃ (%) Yes 123 (5.6%) 38 (5.1%) 34 (5.7%) 32 (6.3%) 19 (5.7%) 
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Characteristics  
Total 
(N=2185) 
Indonesia 
(N=748) 
Peru 
(N=600) 
Romania 
(N=506) 
South Africa 
(N=331) 
Smoking (%) 
 
Current 
Past 
Never 
903 (41.3%) 
355 (16.3%) 
927 (42.4%) 
132 (17.7%) 
331 (44.3%) 
285 (38.1%) 
66 (11%) 
178 (29.7%) 
356 (59.3%) 
233 (46.1%) 
33 (6.5%) 
240 (47.4%) 
273 (82.5%) 
12 (3.6%) 
46 (13.9%) 
Weight loss (%)     
 
(>=10kg)  
(5-10kg)  
(< 5kg) 
163 (7.5%) 
610 (27.9%) 
917 (42.0%) 
67 (9.0%) 
259 (34.6%) 
292 (39.0%) 
30 (5.0%) 
135 (22.5%) 
248 (41.3%) 
20 (4.0%) 
119 (23.5%) 
216 (42.7%) 
46 (13.9%) 
97 (29.3%) 
161 (48.6%) 
Haemoptysis Any 532 (24.4%) 228 (30.5%) 195 (32.5%) 48 (9.5%) 61 (18.4%) 
TB Score  0 to 2 
3 to 5 
6+ 
691 (31.6%) 
1184 (54.2%) 
310 (14.2%) 
109 (14.6%) 
408 (54.6%) 
231 (30.9%) 
274 (45.7%) 
311 (51.2%) 
15 (2.5%) 
251 (49.6%) 
235 (46.4%) 
20 (4.0%) 
57 (17.2%) 
230 (69.5%) 
44 (13.3%) 
Diabetes (%)  No 1348 (61.7%) 523 (69.2%) 464 (77.3%) 209 (41.3%) 152 (45.9%) 
 Pre-DM 458 (21.0%) 90 (12.0%) 82 (13.7%) 199 (39.3%) 87 (26.3%) 
 New DM 84 (3.8%) 32 (4.3%) 12 (2.0%) 31 (6.2%) 3 (0.9%) 
 Known 
DM3 
183 (8.4%) 96 (12.8%) 35 (5.8%) 35 (6.9%) 17 (5.1%) 
 Missing 
data 
57 (2.6%) 3 (0.4%) 1 (0.2%) 0 (0%) 53 (16.0%) 
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Characteristics  
Total 
(N=2185) 
Indonesia 
(N=748) 
Peru 
(N=600) 
Romania 
(N=506) 
South Africa 
(N=331) 
Education ≤ Primary 593 (27.2%) 240 (32.1%) 99 (16.5%) 48 (9.6%) 206 (62.2%) 
 ≥ 
Secondary 
1582 (72.5%) 508 (67.9%) 500 (83.3%) 452 (89.7%) 122 (36.9%) 
Socio-Economic 
Status 
Quintile 1 627 (28.7%) 202 (27.0%) 161 (26.8%) 176 (34.8%) 88 (26.6%) 
 Quintile 2 501 (22.9%) 178 (23.8%) 125 (20.8%) 122 (24.1%) 76 (23.0%) 
 Quintile 3 451 (20.6%) 181 (24.2%) 106 (17.7%) 100 (19.8%) 64 (19.3%) 
 Quintile 4 358 (16.4%) 129 (17.3%) 108 (18.0%) 67 (13.2%) 54 (16.3%) 
 Quintile 5 207 (9.5%) 53 (7.1%) 90 (15.0%) 26 (5.1%) 38 (11.5%) 
 Missing 41 (1.9%) 5 (0.7%) 10 (1.7%) 15 (3.0%) 11 (3.3%) 
 
Figures rounded to 1DP including percentages, percentage given of relevant whole sample with missing values only noted where 
>3%. Some figures may differ from other TANDEM analyses due to minor differences in inclusion criteria or case definitions.  
IQR=interquartile range 
1 obesity in Indonesian population defined as BMI>27.5 kg/m2 
2 HIV status data was only available for 730 patients in Indonesia, 506 in Peru, 364 in Romania and 328 in South Africa. 
3 both self-report of prior DM diagnosis and either (a) use of DM medication or (b) study HbA1c of ≥6.5% 
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Table 2 - Factors associated with DM (new or previously diagnosed) among TB patients over 35 years of age  
 
Factors  
Crude OR (95% 
CI) P-value Adjusted OR (95% CI) P-value 
Age 35-44 years 1  1  
 45-54 years 3.2  (1.4 - 6.6) 0.006 2.9  (1.5 –5.9) 0.004 
 55-64 years 3.8 (2.8 – 5.3) <.0001 3.6  (2.8 – 4.5) <0.001 
 >65 years 3.5 (2.6 – 4.7) <.0001 3.5  (2.3 – 5.3) <0.001 
Gender Female 1  1  
 Male 0.7 (0.5 - 0.9) 0.003 0.9 (0.7 - 1.0) 0.1 
Smear test result Negative 1  1  
 Positive 
Missing 
0.8  (0.4-1.4) 
1.4 (0.9-2.2) 
0.4 
0.09 
0.9 (0.4-1.7) 
1.9 (1.2-3.0) 
0.7 
0.007 
Previous TB episode No 1  1  
 Yes 0.4 (0.3 - 0.6) <.0001 0.5 (0.3 – 0.9) 0.02 
BMI Underweight 0.5 (0.4 - 0.7) <0.001 0.4 (0.3 - 0.5) <0.001 
 Normal 1  1  
 Overweight 2.3 (1.4 – 3.8) 0.001 2.0 (1.3 -3.3) 0.003 
 Obese 5.9 (198 - 17.0) 0.002 6.5 (1.7 – 24.7) 0.006 
Family history of DM No 1  1  
 Yes 3.6 (2.0 - 6.6) <.0001 3.7 (1.8 - 7.3) <0.001 
Socio Economic Status 1 (richest) 1 
 
 1  
2 1.1 (0.8-1.3) 0.5 1.0 (0.7 – 1.4) 0.9 
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Factors  
Crude OR (95% 
CI) P-value Adjusted OR (95% CI) P-value 
3 1.6 (1.3 - 2.1) <0.001 1.2 (1.1- 1.3) <0.001 
4 1.3 (0.8 – 2.1) 0.4 0.8 (0.6- 1.0) 0.08 
5 (poorest) 1.9 (1.0 – 3.7) 0.005
1
 1.43 (0.6 – 2.7) 0.5
1
 
Country (Indonesia as reference) Indonesia 1  
2 
 
Peru 0.5 (0.3-0.8) 0.002   
Romania 0.5 (0.4-0.8) <0.001   
South Africa 0.4 (0.3-0.5) <0.001   
 
1 Wald test for statistical significance across categories of SES, p<0.001  
2 Country entered as a random effect into the adjusted model 
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Table 3. Comparison of TB patients with and without diabetes (TB-DM and TB respectively)  
 
 Total Indonesia Peru Romania South Africa 
 
TB-only 
(N=1918) 
TB-DM 
(N=267) 
p 
TB-only 
(N=620) 
TB-DM 
(N=128) 
p 
TB-only 
(N=553) 
TB-DM 
(N=47) 
p 
TB-only 
(N=440) 
TB-DM 
(N=66) 
P 
TB-only 
(N=305) 
TB-DM 
(N=26) 
p 
Median age (IQR) 
33.0  
(27.0-47.0) 
51.0  
(45.0-59.0) 
<0.001 
34.10 
(25.3-45.0) 
50.5  
(45.1-57.8) 
<0.001 
28.0  
(22.0-39.5) 
51.0  
(47.0-58.0) 
<0.001 
41.0  
(27.0-52.0) 
56.0  
(45.0-65.0) 
<0.001 
32.0  
(27.0-47.0) 
45.5  
(40.5-52.0) 
<0.001 
≥35 years old (%) 48.1% 93.0% <0.001 47.7% 93.8% <0.001 36.7% 91.5% <0.001 63.2% 95.4% <0.001 47.8% 84.6% <0.001 
Gender (% male) 62.0% 55.4% <0.001 58.9% 47.7% 0.02 58.6% 51.1% 0.3 69.8% 77.3% 0.2 63.3% 46.2% 0.08 
Previous TB (%) 25.7% 16.9% 0.02 25.7% 20.3% 0.3 21.0% 14.9% 0.3 20.2% 12.1% 0.09 42.3% 15.4% 0.007 
Smoking* (%) 
Current 
smoker 
42.7% 31.8% 
0.002 
46.5% 33.6% 
0.002 
11.9% 0% 
0.001 
47.5% 36.4% 
0.03 
83.6% 69.2% 
0.001 
Past 
smoker 
16.2% 16.5% 17.3% 19.5% 30.2% 23.4% 6.4% 7.6% 3% 11.5% 
Never 
smoker 
41.1% 51.7% 36.3% 46.9% 57.9% 76.6% 46.1% 56.1% 13.4% 19.2% 
Median BMI (kg/m2) 
19.6  
(17.6-22.1) 
21.9  
(19.0-25.7) 
<0.001 
17.9 
(16.1-19.9) 
21.1  
(18.4-24.9) 
<0.001 
21.9  
(19.9-24.1) 
24.7  
(21.8-28.4) 
<0.001 
20.2  
(18.5-22.0) 
21.4  
(19.3-23.9) 
0.02 
18.4  
(16.9-20.3) 
22.3  
(18.6-27.0) 
0.004 
Mean WHR 
 
Men 
(SD) 
 
0.86  
(0.067) 
0.89  
(0.077) 
<0.001 
0.83  
(0.068) 
0.88  
(0.063) 
<0.0001 
0.89 
(0.060) 
0.95 
(0.067) 
<0.0001 
0.86 
(0.063) 
0.88 
(0.088) 
0.07 
0.86 
(0.059) 
0.89 
(0.072) 
0.063 
 
Women 
(SD) 
0.83  
(0.073) 
0.87 (0.077) <0.001 
0.81  
(0.071) 
0.86  
(0.072) 
<0.0001 
0.87 
(0.062) 
0.91 
(0.078) 
0.007 
0.79 
(0.072) 
0.829 
(0.090) 
0.06 
0.83  
(0.58) 
0.89 
(0.056) 
0.001 
Mean Laboratory HbA1c(%) 
5.6  
(5.3-5.9) 
10.4 
(7.9–12.3) 
 
5.5  
(5.3–5.8) 
11.3  
(9.1–12.9) 
<0.001 
5.5  
(5.2–5.8) 
10.6  
(9.0–13.3) 
<0.001 
5.8  
(5.5–6.1) 
7.4  
(6.7-10.8)1 
 
5.8  
(5.5–6.1) 
10.1  
(7.8–11.9) 
<0.001 
Antihypertensive 
medication use (%) 
3.2% 16.9% <0.001 4.0% 13.3% <0.001 0.5% 8.5% <0.001 4.1% 22.7% <0.001 5.0% 34.6% <0.001 
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 Total Indonesia Peru Romania South Africa 
 
TB-only 
(N=1918) 
TB-DM 
(N=267) 
p 
TB-only 
(N=620) 
TB-DM 
(N=128) 
p 
TB-only 
(N=553) 
TB-DM 
(N=47) 
p 
TB-only 
(N=440) 
TB-DM 
(N=66) 
P 
TB-only 
(N=305) 
TB-DM 
(N=26) 
p 
CVD Risk (% with 10 year risk 
estimated over 10%)  
5.5% 24.5% 0.06 7.0%% 17.9& 0.1 2.8% 22.2% 0.02 5.24% 38% <0.001 5.5% 8.3$ 0.2 
Smear positive (%) 72.7% 80.2% 0.009 83.1% 89.1% 0.09 64.2% 68.1% 0.6 67.5% 72.7% 0.4 67.2% 65.4% 1.0 
Culture positive (%) 81.4% 91.5% <0.001 79.5% 91.4% 0.002 82.1% 89.4% 0.2 76.1% 83.3% 0.1 83.7% 88.0% 1.0 
Smear grade (max at baseline, %) 
Negative 
Scanty and 1+ 
2+ and 3+ 
 
26.8% 
31.3% 
40.3% 
 
19.5% 
30.3% 
48.7% 
0.0001 
 
16.8% 
29.4% 
53.7% 
 
10.9% 
26.6% 
62.5% 
0.2 
 
35.4% 
31.7% 
32.6% 
 
32.0% 
29.8% 
38.3% 
0.8 
 
29.8% 
33.0% 
34.6% 
 
24.2% 
34.9% 
37.9% 
0.8 
 
26.9% 
32.1% 
35.1% 
 
26.9% 
38.5% 
26.9% 
0.8 
Anaemia amongst men (%)2 46.9% 43.2% 0.8 56.1% 29.5 <0.001 30.3% 37.5% 0.5 42.4% 53.0% 0.2 66.8% 83.3% 0.2 
Anaemia amongst women (%)2 52.1% 42.0% 0.001 61.9% 49.2 0.06 38.4% 26.1% 0.2 48.1% 40.0% 0.6 62.5% 35.7% 0.05 
Haemoptysis (%) 23.6% 30.0% 0.1 28.9% 38.3 0.03 32.2% 36.2% 0.8 8.9% 13.6% 0.02 18.4% 19.2% 0.6 
TB Score 
0 to 2 31.8% 30.7% 
0.03 
 
13.8% 
18.0% 
P<0.001 
45.3% 48.9% 
0.5 
50.7% 42.4% 
0.3 
16.1% 30.8% 
0.09 3 to 5 53.4% 60.0% 52.1% 66.4% 51.9% 51.1% 45.7% 51.5% 69.8% 65.4% 
6+ 14.9% 9.4% 34.0% 15.6% 2.7% 0.0% 3.6% 6.1% 14.1% 3.8% 
 
Figures rounded to 1 decimal place including percentages, percentage given of relevant whole sample with missing values only 
shown where >3% 
1   In Romania, where TB patients are treated as in-patients, repeated FBG measurements were available. 9 of 66 DM patients were 
classified using FBG rather than repeated HbA1c 
2  Anaemia defined as Hb<13 in men (n=1337) and <12 in women (n=846) 
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Table 4 – Comparative characteristics of TB patients with newly and previously diagnosed DM 
 
  
New DM 
(N=84) 
Known DM 
(N=183) 
P-values 
Median Age in years (IQR)  52.0 (45.1-62.0) 51.0 (45.1-59.0) 0.9 
Gender (%) Male 52 (61.9%) 96 (52.5%) 0.2 
Haemoptysis  28 (35.4%) 52 (32.1%) 0.2 
TB Score  0 to 2 
3 to 5 
6+ 
19 (22.3%) 
51 (60.7%) 
14 (16.7%) 
63 (34.4%) 
109 (59.6%) 
11 (6.0%) 
<0.001 
Median BMI kg/m2 (IQR)  20.0 (17.9-24.5) 22.5 (19.7-25.9) 0.02 
Median HbA1c% (IQR) Lab  8.0 (6.8-11.7) 10.9 (9.1-12.6) 0.05  
 Repeat 6.9 (6.5-12.4) 10.8 (8.9-12.4) 0.2 
Duration of DM diagnosis N (%) < 1 year NA 53 (29.0%)  
 1-5 years NA 77 (42.1%)  
 6-15 years NA 42 (23.0%)  
 15+ years NA 11 (6.0%)  
Treatment including Insulin N  NA 37 (20.2%)  
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New DM 
(N=84) 
Known DM 
(N=183) 
P-values 
(%) 
Treatment including Metformin 
N (%) 
 NA 112 (61.2%)  
Any hospital admission in the 
last 5 years due to DM N (%) 
 NA 36 (20.0%)  
Family history of DM N (%)  16 (19.1%) 79 (43.2%) <0.001 
CMI score ≥ 2 (%)  2 (2.4%) 86 (47.0%) <0.001 
Any Diabetes Complication (%)  2 (2.4%) 79 (43.2%) <0.001 
Hypertension Pre-hypertension N 
(%) 
13 (15.5%) 15 (8.2%) <0.001 1 
Stage I N (%) 21 (25%) 48 (26.2%)  
Stage II N (%) 18 (21.4%) 59 (32.2%)  
Antihypertensive medication N (%) 7 (8.3%) 38 (20.8%) 0.006 
Renal function N (%) CKD Stage 3-5  
(eGFR < 60) 
2 (2.4%) 10 (5.5%) 0.3 
Figures rounded to 1DP including percentages, percentage given of relevant whole sample with missing values only shown where 
>3% 
IQR=interquartile range,  
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CMI=Charlson co-morbidity index. 
NA: Not Applicable 
1 Wald test for statistical significance across categories of hypertension, p<0.001  
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